Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 12:52 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2377–2400 of 8,174 matching trials from the live ClinicalTrials.gov search.

Filters: Phoenix, Arizona Clear all

Conditions: Alzheimer Disease
Interventions: Donepezil TDS Version A, Donepezil TDS Version B, Aricept, Donepezil TDS Version D, Donepezil TDS Version E; Drug
Lead sponsor: Corium, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Metastatic Malignant Neoplasm in the Brain
Interventions: Brain Surgery, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery; Procedure · Other · Radiation
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 208
States / cities: Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 154 more

Conditions: Quality of Life Outcomes
Interventions: Pediatric Palliative Care Consultation; Behavioral
Lead sponsor: Phoenix Children's Hospital; Other
Eligibility: 0 Years to 25 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Phoenix, Arizona • Bethesda, Maryland • Memphis, Tennessee

Conditions: Vulvovaginitis, Yeast Infection, Yeast Infection Vaginal, Candidiasis, Vulvovaginal
Interventions: Oral Encochleated Amphotericin B (CAMB), Fluconazole; Drug
Lead sponsor: Matinas BioPharma Nanotechnologies, Inc.; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 23
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more

Conditions: Pain
Interventions: Buffered Lidocaine J-tip; Drug
Lead sponsor: Phoenix Children's Hospital; Other
Eligibility: Up to 90 Days
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Dehydration, Diabetes Mellitus, Type 2
Interventions: Water Intake; Other
Lead sponsor: Arizona State University; Other
Eligibility: 30 Years to 55 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Pain, Postoperative
Interventions: pregabalin (Lyrica), matched placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 25 Years to 70 Years · Female only
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 14
States / cities: Mobile, Alabama • Glendale, Arizona • Phoenix, Arizona + 6 more

Conditions: Gastroesophageal Reflux Disease
Interventions: SSP-002358 (0.1 mg) + PPI, SSP-002358 (0.5 mg) + PPI, SSP-002358 (2.0 mg) + PPI, Placebo + PPI; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 62
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 58 more

Conditions: Incontinence, Urinary and Urinary Bladder, Overactive, Overactive Bladder
Interventions: GW679769 oral tablets; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 41
States / cities: Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 36 more

Conditions: COPD
Interventions: QAB149; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 686 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 54
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 44 more

Conditions: Influenza
Interventions: Amantadine, Ribavirin, Oseltamivir, Oseltamivir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 881 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 69
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 58 more

Conditions: B-Cell Malignancies
Interventions: Parsaclisib, parsaclisib + itacitinib, parsaclisib + ruxolitinib, parsaclisib + ibrutinib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 26
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 20 more

Conditions: Migraine, Migraine With Aura, Migraine Without Aura
Interventions: Dihydroergotamine, Placebos; Drug
Lead sponsor: Satsuma Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 117
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 96 more

Conditions: Hidradenitis Suppurativa
Interventions: Bimekizumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 505 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more

Conditions: Partial Epilepsies, Partial Onset Seizures
Interventions: lacosamide; Drug
Lead sponsor: UCB BIOSCIENCES, Inc.; Industry
Eligibility: 16 Years to 60 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 7
States / cities: Phoenix, Arizona • Baltimore, Maryland • Chesterfield, Missouri + 4 more

Conditions: Sarcoma, Giant Cell Tumor of Bone
Interventions: Surgery; Procedure
Lead sponsor: University of Calgary; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 2
States / cities: Phoenix, Arizona • Rochester, Minnesota

Conditions: Multiple Sclerosis
Interventions: Daclizumab (Anti-CD25 Humanized Monoclonal Antibody); Drug
Lead sponsor: PDL BioPharma, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 30
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Berkeley, California + 26 more

Conditions: Neuroblastoma, Sarcoma
Interventions: Cyclophosphamide, Topotecan, and Bevacizumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 21 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 6
States / cities: Phoenix, Arizona • Denver, Colorado • Orlando, Florida + 3 more

Conditions: Migraine
Interventions: Eptinezumab, Placebo; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 52
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 48 more

Conditions: Sedation
Interventions: A. CNS 7056, B. CNS 7056, C. CNS 7056, D. Midazolam; Drug
Lead sponsor: Paion UK Ltd.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 9
States / cities: Sheffield, Alabama • Phoenix, Arizona • Anaheim, California + 5 more

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: Pamrevlumab, Placebo; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 393 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 60
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more

Conditions: Hypertension
Interventions: Nebivolol, Valsartan and Hydrochlorothiazide; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 812 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 135
States / cities: Birmingham, Alabama • Foley, Alabama • Gulf Shores, Alabama + 113 more

Conditions: Hypertension
Interventions: Irbesartan/HCTZ, Irbesartan monotherapy; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 645 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 156
States / cities: Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 153 more

Conditions: Aortic Aneurysm
Interventions: Endoluminal Graft; Device
Lead sponsor: Arizona Heart Institute; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2012
U.S. locations: 1
States / cities: Phoenix, Arizona

Search by objective public record fields.

A Phase 1, Corplex™ Donepezil Transdermal System Compared to Oral Aricept®

Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases

Palliative Care Integration in Pediatric Oncology Phase 1 Clinical Trials

Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)

Needle-Free Jet Injection of Lidocaine During Lumbar Puncture

INDIGO-2: The Effect of High Water Intake on Glucose Regulation in Low-drinkers

Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo For Treatment Of Post-Surgical Pain From Hysterectomy

Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)

A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder

Dose-Ranging Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures

Activation Sarcoma: PROMIS and Mobility Evaluation in Sarcoma Patients

Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis

Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma

A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine

Multiple Dose Safety and Efficacy Study Evaluating CNS 7056 Versus Midazolam in Patients Undergoing Colonoscopy

Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension

Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension

Abdominal Aortic/Aorto-Iliac Aneurysm Endoluminal Graft Study